The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

Head and Neck Cancer

See how Bayer is investigating head and neck cancer across the pipeline

Follow the connections from areas of research to investigational compounds and the clinical trials evaluating them.

Head and neck cancer icon

Head and Neck Cancer Overview

Bayer’s head and neck cancer research includes an investigational program targeting the KEAP1-NRF2 pathway, which plays a role in the cellular response to oxidative stress.

This program connects KEAP1 signaling with an investigational compound and the clinical trial evaluating it across multiple tumor types.

1 investigational compound

1 area of research

1 clinical trial

Compound

KEAP1-NRF2 inhibitor (BAY 3605349)

Area of Research

KEAP1 signaling

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Lung Cancer, Solid Tumors, Head and Neck Cancer

I

Now Enrolling

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

NCT05954312

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.

KEAP1, Kelch-like ECH-associated protein 1; NRF2, nuclear factor erythroid 2–related factor 2.